{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T08:12:54Z","timestamp":1767168774302,"version":"3.48.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T00:00:00Z","timestamp":1704758400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.prp.2024.155107","type":"journal-article","created":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T12:16:05Z","timestamp":1704802565000},"page":"155107","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Predictive factors for complete pathological response in hormone receptor-negative breast cancer patients undergoing neoadjuvant chemotherapy"],"prefix":"10.1016","volume":"254","author":[{"given":"George","family":"Dimitrov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petranka","family":"Troianova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.prp.2024.155107_bib1","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA: a Cancer J. Clin."},{"issue":"10286","key":"10.1016\/j.prp.2024.155107_bib2","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/S0140-6736(20)32381-3","article-title":"Breast cancer","volume":"397","author":"Loibl","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.prp.2024.155107_bib3","doi-asserted-by":"crossref","first-page":"691","DOI":"10.6004\/jnccn.2022.0030","article-title":"Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Gradishar","year":"2022","journal-title":"J. Natl. Compr. Cancer Netw.: Jnccn."},{"issue":"9938","key":"10.1016\/j.prp.2024.155107_bib4","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.prp.2024.155107_bib5","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1038\/s41467-022-30342-3","article-title":"Proteogenomic characterization of 2002 human cancers reveals pan-cancer molecular subtypes and associated pathways","volume":"13","author":"Zhang","year":"2022","journal-title":"Nat. Commun."},{"issue":"18","key":"10.1016\/j.prp.2024.155107_bib6","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1200\/JCO.2001.19.18.3817","article-title":"Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer","volume":"19","author":"Goldhirsch","year":"2001","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.prp.2024.155107_bib7","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1200\/JCO.22.02241","article-title":"Pathologic complete response and individual patient prognosis after neoadjuvant chemotherapy plus anti-human epidermal growth factor receptor 2 therapy of human epidermal growth factor receptor 2-positive early breast cancer","volume":"41","author":"van Mackelenbergh","year":"2023","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2024.155107_bib8","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1186\/s12885-020-07621-7","article-title":"Nomogram-derived prediction of pathologic complete response (pCR) in breast cancer patients treated with neoadjuvant chemotherapy (NCT)","volume":"20","author":"Pu","year":"2020","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.prp.2024.155107_bib9","doi-asserted-by":"crossref","first-page":"936","DOI":"10.7150\/jca.52439","article-title":"Novel biomarkers and prediction model for the pathological complete response to neoadjuvant treatment of triple-negative breast cancer","volume":"12","author":"Han","year":"2021","journal-title":"J. Cancer"},{"issue":"12","key":"10.1016\/j.prp.2024.155107_bib10","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1038\/sj.bjc.6602235","article-title":"Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer","volume":"91","author":"Ring","year":"2004","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.prp.2024.155107_bib11","doi-asserted-by":"crossref","first-page":"213","DOI":"10.5152\/ejbh.2020.5487","article-title":"Evaluation of pathologic complete response (pCR) to Neoadjuvant Chemotherapy in Iranian Breast Cancer Patients with Estrogen Receptor Positive and HER2 Negative and impact of predicting variables on pCR","volume":"16","author":"Omranipour","year":"2020","journal-title":"Eur. J. Breast Health"},{"issue":"1","key":"10.1016\/j.prp.2024.155107_bib12","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12957-022-02492-7","article-title":"Exploring the influencing factors of the pathologic complete response in estrogen receptor-positive, HER2-negative breast cancer after neoadjuvant chemotherapy: a retrospective study","volume":"20","author":"Tang","year":"2022","journal-title":"World J. Surg. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2024.155107_bib13","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3892\/etm.2011.359","article-title":"Predictive significance of the proportion of ER-positive or PgR-positive tumor cells in response to neoadjuvant chemotherapy for operable HER2-negative breast cancer","volume":"3","author":"Osako","year":"2012","journal-title":"Exp. Ther. Med."},{"issue":"1","key":"10.1016\/j.prp.2024.155107_bib14","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.bj.2018.10.007","article-title":"Impact of age on pathological complete response and locoregional recurrence in locally advanced breast cancer after neoadjuvant chemotherapy","volume":"42","author":"Chou","year":"2019","journal-title":"Biomed. J."},{"issue":"6","key":"10.1016\/j.prp.2024.155107_bib15","doi-asserted-by":"crossref","first-page":"e741","DOI":"10.1016\/j.clbc.2019.05.014","article-title":"Does tumor size predict response to neoadjuvant chemotherapy in the modern era of biologically driven treatment? A nationwide study of US breast cancer patients","volume":"19","author":"Livingston-Rosanoff","year":"2019","journal-title":"Clin. Breast Cancer"},{"issue":"1","key":"10.1016\/j.prp.2024.155107_bib16","doi-asserted-by":"crossref","first-page":"9934","DOI":"10.1038\/s41598-019-46309-2","article-title":"Overall survival is improved when DCIS accompanies invasive breast cancer","volume":"9","author":"Kole","year":"2019","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.prp.2024.155107_bib17","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10549-010-1228-x","article-title":"Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials","volume":"125","author":"von Minckwitz","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"issue":"18","key":"10.1016\/j.prp.2024.155107_bib18","doi-asserted-by":"crossref","first-page":"484","DOI":"10.21037\/atm.2019.08.16","article-title":"The prognostic significance of co-existence ductal carcinoma in situ in invasive ductal breast cancer: a large population-based study and a matched case-control analysis","volume":"7","author":"Chen","year":"2019","journal-title":"Ann. Transl. Med."},{"issue":"2","key":"10.1016\/j.prp.2024.155107_bib19","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s10549-012-2289-9","article-title":"Role of epidermal growth factor receptor in breast cancer","volume":"136","author":"Masuda","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"issue":"2","key":"10.1016\/j.prp.2024.155107_bib20","first-page":"413","article-title":"EGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancer","volume":"21","author":"Nogi","year":"2009","journal-title":"Oncol. Rep."},{"issue":"1","key":"10.1016\/j.prp.2024.155107_bib21","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/PPO.0b013e3181d24fc1","article-title":"Epidermal growth factor receptor in triple-negative and basal-like breast cancer: promising clinical target or only a marker?","volume":"16","author":"Burness","year":"2010","journal-title":"Cancer J."},{"issue":"5","key":"10.1016\/j.prp.2024.155107_bib22","article-title":"Can EGFR be a therapeutic target in breast cancer?","volume":"1877","author":"Li","year":"2022","journal-title":"Biochim. Et. Biophys. Acta (BBA) - Rev. Cancer"},{"issue":"1","key":"10.1016\/j.prp.2024.155107_bib23","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.bbapap.2004.11.001","article-title":"Involvement of neutral endopeptidase in neoplastic progression","volume":"1751","author":"Sumitomo","year":"2005","journal-title":"Biochim. Et. Biophys. Acta"},{"issue":"8","key":"10.1016\/j.prp.2024.155107_bib24","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.neo.2017.05.002","article-title":"UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses","volume":"19","author":"Chandrashekar","year":"2017","journal-title":"Neoplasia"},{"issue":"1","key":"10.1016\/j.prp.2024.155107_bib25","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2217\/whe.15.99","article-title":"Breast cancer subtypes: morphologic and biologic characterization","volume":"12","author":"Masood","year":"2016","journal-title":"Women'S. Health"},{"issue":"3","key":"10.1016\/j.prp.2024.155107_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics13030372","article-title":"Expression of the Immunohistochemical Markers CK5, CD117, and EGFR in molecular subtypes of breast cancer correlated with prognosis","volume":"13","author":"Schulmeyer","year":"2023","journal-title":"Diagnostics"},{"key":"10.1016\/j.prp.2024.155107_bib27","article-title":"Analysis of CK5\/6 and EGFR and its effect on prognosis of triple negative breast cancer","volume":"10","author":"Wang","year":"2021","journal-title":"Front. Oncol."}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033824000189?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033824000189?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T08:09:19Z","timestamp":1767168559000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033824000189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":27,"alternative-id":["S0344033824000189"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2024.155107","relation":{},"ISSN":["0344-0338"],"issn-type":[{"type":"print","value":"0344-0338"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictive factors for complete pathological response in hormone receptor-negative breast cancer patients undergoing neoadjuvant chemotherapy","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2024.155107","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"155107"}}